REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
April 18, 2022 16:00 ET
|
Heat Biologics
DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
April 18, 2022 08:30 ET
|
Heat Biologics
500,000+ square foot facility to support commercial-scale biomanufacturing Livestreaming ceremony with Governor Laura Kelly Live from Manhattan, Kansas today at 11:00am ET/ 10:00am CT today at...
Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
April 14, 2022 12:35 ET
|
Heat Biologics
DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
March 25, 2022 08:00 ET
|
Heat Biologics
DURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and...
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
March 23, 2022 08:30 ET
|
Heat Biologics
DURHAM, N.C., March 23, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and...
Heat Biologics Provides Year-End 2021 Business Update
March 14, 2022 08:00 ET
|
Heat Biologics
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
Heat Biologics Announces Planned Transfer to the NYSE American
February 02, 2022 16:05 ET
|
Heat Biologics
DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
January 31, 2022 07:30 ET
|
Heat Biologics; Elusys Therapeutics, Inc.
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S....
Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110
January 12, 2022 08:00 ET
|
Heat Biologics
DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
December 21, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...